Evaluation On The Safety of Anti-Platelet Agents In Patients With Acute Pancreatitis: A Retrospective Cohort Study
Bibliographic record
Abstract
Abstract Background: Anti-platelet drug has not been paid much attention in guidelines for the treatment of acute pancreatitis, especially in patients with cardiovascular disease and receiving anti-platelet therapy, and its safety hasn’t been evaluated by any guidelines or studies. Methods: A total of 904 patients with acute pancreatitis were enrolled in this cohort study, they were divided into Anti-platelet therapy group (n=297) and non-Anti-platelet therapy group (n=607). The primary result was the mortality in the 14th-day, 28th-day, and 90th-day. Adverse events during treatment included septic shock, respiratory tract infection, urinary tract infection, abdominal infection, bleeding, kidney damage, respiratory distress, cardiac dysfunction, liver dysfunction, and renal dysfunction. Kaplan-meier, propensity score matching (PSM), subsequently, cox regression and subgroup analysis were performed. Results: The mortality rates were 9.55% vs 4.71%, P =0.012,13.34% vs 8.1%, P =0.02,16.14% vs 13.13%, P =0.235, respectively, during the 14-day, 28-day, and 90-day follow-up periods. Risk ratio for death among anticoagulants versus non-anticoagulants after multivariate adjustment (HR=2.815,2.819, 95%CI:1.021-4.667,1.045-4.583, p < 0.05). According to the survival curves, there were significant differences in mortality after 14, 28, and 90 days between the anticoagulant and non-anticoagulant groups (log-rank P<0.05). After PSM, 297 pairs were identified, and there was no significant difference in the risk of death between the anticoagulant and non-anticoagulant groups (all P >0.05). Conclusions: Anti-platelet therapy is not superior to non-prophylactic anti-platelet therapy in terms of reducing mortality and adverse events in acute pancreatitis, and there is no statistically significant difference in mortality and adverse events in the cohort of cardiovascular patients using anti-platelet drugs compared with those without using anti-platelet drugs.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".